Canada funds denosumab, telaprevir and rivaroxaban

Author：  

Publisher： Adis International

ISSN： 1173-5503

Source： PharmacoEconomics and Outcomes News, Vol.1, Iss.653, 2012-01, pp. : 10-10

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Positive NICE recommendations for rivaroxaban and denosumab

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 651, 2012-01 ,pp. : 11-11

Adis International

Access to resources Recommend Favorite

Greater access to denosumab and boceprevir in Canada

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 643, 2011-01 ,pp. : 10-10

Adis International

Access to resources Recommend Favorite

Telaprevir

By  

Drugs in R&D, Vol. 10, Iss. 3, 2010-09 ,pp. : 179-202

Adis International

Access to resources Recommend Favorite

Amgen Canada Inc. is warning of the risk of atypical femoral fracture associated with use of the osteoporosis treatment, Prolia [denosumab].

By  

Reactions Weekly, Vol. 1, Iss. 1430, 2012-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite

Telaprevir for the treatment of hepatitis C

By Forestier Nicole   Zeuzem Stefan  

Expert Opinion on Pharmacotherapy, Vol. 13, Iss. 4, 2012-03 ,pp. : 593-606

Informa Healthcare

Access to resources Recommend Favorite